London Daily

Focus on the big picture.
Monday, Oct 20, 2025

Oxford vaccine triggers immune response

A coronavirus vaccine developed by the University of Oxford appears safe and triggers an immune response.

Trials involving 1,077 people showed the injection led to them making antibodies and T-cells that can fight coronavirus.

The findings are hugely promising, but it is still too soon to know if this is enough to offer protection and larger trials are under way.

The UK has already ordered 100 million doses of the vaccine.


How does the vaccine work?

The vaccine - called ChAdOx1 nCoV-19 - is being developed at unprecedented speed.

It is made from a genetically engineered virus that causes the common cold in chimpanzees.

It has been heavily modified, first so it cannot cause infections in people and also to make it "look" more like coronavirus.

Scientists did this by transferring the genetic instructions for the coronavirus's "spike protein" - the crucial tool it uses to invade our cells - to the vaccine they were developing.

This means the vaccine resembles the coronavirus and the immune system can learn how to attack it.


What are antibodies and T-cells?

Much of the focus on coronavirus so far has been about antibodies, but these are only one part of our immune defence.

Antibodies are small proteins made by the immune system that stick onto the surface of viruses.

Neutralising antibodies can disable the coronavirus.

T-cells, a type of white blood cell, help co-ordinate the immune system and are able to spot which of the body's cells have been infected and destroy them.

Nearly all effective vaccines induce both an antibody and a T-cell response.

Levels of T-cells peaked 14 days after vaccination and antibody levels peaked after 28 days. The study has not run for long enough to understand how long they may last, the study in the Lancet showed.

Prof Andrew Pollard, from the Oxford research group told the BBC: "We're really pleased with the results published today as we're seeing both neutralising antibodies and T-cells.

"They're extremely promising and we believe the type of response that may be associated with protection.

"But the key question everyone wants to know is does the vaccine work, does it offer protection... and we're in a waiting game."

The study showed 90% of people developed neutralising antibodies after one dose. Only ten people were given two doses and all of them produced neutralising antibodies.

"We don't know the level needed for protection, but we can maximise responses with a second dose," Prof Pollard told the BBC.


Is it safe?

Yes, but there are side-effects.

There were no dangerous side-effects from taking the vaccine, however, 70% of people on the trial developed either fever or headache.

The researchers say this could be managed with paracetamol.

Prof Sarah Gilbert, from the University of Oxford, UK, says: "There is still much work to be done before we can confirm if our vaccine will help manage the Covid-19 pandemic, but these early results hold promise."

What are the next steps in the trial?
The results so far are promising, but their main purpose is to ensure the vaccine is safe enough to give to people.

The study cannot show whether the vaccine can either prevent people from becoming ill or even lessen their symptoms of Covid-19.

More than 10,000 people will take part in the next stage of the trials in the UK.

However, the trial has also been expanded to other countries because levels of coronavirus are low in the UK, making it hard to know if the vaccine is effective.

There will be a large trial involving 30,000 people in the US as well 2,000 in South Africa and 5,000 in Brazil.

There are also calls to perform "challenge trials" in which vaccinated people are deliberately infected with coronavirus. However, there are ethical concerns due to a lack of treatments.


When will I get a vaccine?

It is possible a coronavirus vaccine will be proven effective before the end of the year, however, it will not be widely available.

Health and care workers will be prioritised as will people who are deemed at high risk from Covid-19 due to their age or medical conditions.

However, widespread vaccination is likely to be, at the earliest, next year even if everything goes to plan.

Boris Johnson said: "Obviously I'm hopeful, I've got my fingers crossed, but to say I'm 100% confident we'll get a vaccine this year, or indeed next year, is, alas, just an exaggeration.

"We're not there yet."

What progress is being made with other vaccines?
The Oxford vaccine is not the first to reach this stage, with groups in the US and China also publishing similar results.

The US company Moderna was first out of the blocks and its vaccine can produce neutralising antibodies. They are injecting coronavirus RNA (its genetic code), which then starts making viral proteins in order to trigger an immune response.

The companies BioNtech and Pfizer have also had positive results using their RNA vaccine.

A technique similar to the Oxford one, developed in China, also seems promising.

However, all these approaches are at the absolute boundary of science and have not been proven to work before.

More traditional methods of vaccine development are also being investigated. The company Valneva is taking the whole coronavirus, inactivating it and then inject it.

In total there are 23 coronavirus vaccines in clinical trials around the world and another 140 in early stage development.


Will the UK get a coronavirus vaccine?

The UK government has struck deals for 190 million doses of different vaccines.

This includes:

100 million doses of the Oxford vaccine made from a genetically engineered virus
30 million doses of the BioNtech/Pfizer vaccine, which injects part of the coronavirus' genetic code
60 million doses of the Valneva inactivated coronavirus
These have been paid for even though it is uncertain which, if any, of the vaccines may prove effective for immunising a nation with 66m people.

Kate Bingham, chairwoman of the UK Vaccine Taskforce, told the BBC: "What we are doing is identifying the most promising vaccines across the different categories, or different types of vaccine, so that we can be sure that we do have a vaccine in case one of those actually proves to be both safe and effective.

"It's unlikely to be a single vaccine for everybody.

"We may well need different vaccines for different groups of people."

Newsletter

Related Articles

0:00
0:00
Close
China Warns UK of ‘Consequences’ After Delay to London Embassy Approval
France’s Wealthy Shift Billions to Luxembourg and Switzerland Amid Tax and Political Turmoil
"Sniper Position": Observation Post Targeting 'Air Force One' Found Before Trump’s Arrival in Florida
Shouting Match at the White House: 'Trump Cursed, Threw Maps, and Told Zelensky – "Putin Will Destroy You"'
Windows’ Own ‘Siri’ Has Arrived: You Can Now Talk to Your Computer
Thailand and Singapore Investigate Cambodian-Based Prince Group as U.S. and U.K. Sanctions Unfold
‘No Kings’ Protests Inflate Numbers — But History Shows Nations Collapse Without Strong Executive Power
Chinese Tech Giants Halt Stablecoin Launches After Beijing’s Regulatory Intervention
Manhattan Jury Holds BNP Paribas Liable for Enabling Sudanese Government Abuses
Trump Orders Immediate Release of Former Congressman George Santos After Commuting Prison Sentence
S&P Downgrades France’s Credit Rating, Citing Soaring Debt and Political Instability
Ofcom Rules BBC’s Gaza Documentary ‘Materially Misleading’ Over Narrator’s Hamas Ties
Diane Keaton’s Cause of Death Revealed as Pneumonia, Family Confirms
Former Lostprophets Frontman Ian Watkins Stabbed to Death in British Prison
"The Tsunami Is Coming, and It’s Massive": The World’s Richest Man Unveils a New AI Vision
Outsider, Heroine, Trailblazer: Diane Keaton Was Always a Little Strange — and Forever One of a Kind
Dramatic Development in the Death of 'Mango' Founder: Billionaire's Son Suspected of Murder
Two Years of Darkness: The Harrowing Testimonies of Israeli Hostages Emerging From Gaza Captivity
EU Moves to Use Frozen Russian Assets to Buy U.S. Weapons for Ukraine
Europe Emerges as the Biggest Casualty in U.S.-China Rare Earth Rivalry
HSBC Confronts Strategic Crossroads as NAB Seeks Only Retail Arm in Australia Exit
U.S. Chamber Sues Trump Over $100,000 H-1B Visa Fee
Shenzhen Expo Spotlights China’s Quantum Step in Semiconductor Self-Reliance
China Accelerates to the Forefront in Global Nuclear Fusion Race
Yachts, Private Jets, and a Picasso Painting: Exposed as 'One of the Largest Frauds in History'
Australia’s Wedgetail Spies Aid NATO Response as Russian MiGs Breach Estonian Airspace
McGowan Urges Chalmers to Cut Spending Over Tax Hike to Close $20 Billion Budget Gap
Victoria Orders Review of Transgender Prison Placement Amid Safety Concerns for Female Inmates
U.S. Treasury Mobilises New $20 Billion Debt Facility to Stabilise Argentina
French Business Leaders Decry Budget as Macron’s Pro-Enterprise Promise Undermined
Trump Claims Modi Pledged India Would End Russian Oil Imports Amid U.S. Tariff Pressure
Surging AI Startup Valuations Fuel Bubble Concerns Among Top Investors
Australian Punter Archie Wilson Tears Up During Nebraska Press Conference, Sparking Conversation on Male Vulnerability
Australia Confirms U.S. Access to Upgraded Submarine Shipyard Under AUKUS Deal
“Firepower” Promised for Ukraine as NATO Ministers Meet — But U.S. Tomahawks Remain Undecided
Brands Confront New Dilemma as Extremists Adopt Fashion Labels
The Sydney Sweeney and Jeans Storm: “The Outcome Surpassed Our Wildest Dreams”
Erika Kirk Delivers Moving Tribute at White House as Trump Awards Charlie Presidential Medal of Freedom
British Food Influencer ‘Big John’ Detained in Australia After Visa Dispute
ScamBodia: The Chinese Fraud Empire Shielded by Cambodia’s Ruling Elite
French PM Suspends Macron’s Pension Reform Until After 2027 in Bid to Stabilize Government
Orange, Bouygues and Free Make €17 Billion Bid for Drahi’s Altice France Telecom Assets
Dutch Government Seizes Chipmaker After U.S. Presses for Removal of Chinese CEO
Bessent Accuses China of Dragging Down Global Economy Amid New Trade Curbs
U.S. Revokes Visas of Foreign Nationals Who ‘Celebrated’ Charlie Kirk’s Assassination
AI and Cybersecurity at Forefront as GITEX Global 2025 Kicks Off in Dubai
DJI Loses Appeal to Remove Pentagon’s ‘Chinese Military Company’ Label
EU Deploys New Biometric Entry/Exit System: What Non-EU Travelers Must Know
Australian Prime Minister’s Private Number Exposed Through AI Contact Scraper
Ex-Microsoft Engineer Confirms Famous Windows XP Key Was Leaked Corporate License, Not a Hack
×